AxoGen, Inc. is screened out under 2 exclusion reasons spanning 1 issue category.
This page is part of our public exclusion list — a transparency tool that shows which companies we screen out and why. It is not investment advice, and it is not an accusation. It is a statement of values.
Axogen, Inc. develops and markets processed nerve allografts, primarily its Avance Nerve Graft product, which are derived from donated human tissue. The company's core business model involves the commercial processing and sale of human tissue for surgical implantation. This activity constitutes commercial exploitation of human biological material on an industrial scale, with the company reporting over 100,000 such grafts implanted to date. The sourcing, processing, and sale of human tissue for profit falls under the broad ethical exclusion for commercial exploitation of biological material from sentient beings.
The company's regulatory filings and legal documents highlight significant and recurring legal risks associated with its business model, including litigation and federal investigations into violations of the Anti-Kickback Statute and the False Claims Act. These proceedings often concern the company's promotional practices and financial relationships with healthcare providers, indicating systemic governance issues tied to its commercial tissue operations. While the donated tissue is human-sourced, the industrial-scale commodification and associated pattern of legal entanglements align this activity with the ethical concerns of the animal exploitation category, specifically where commercial systems are designed to exploit biological material.
Axogen, Inc. develops and markets surgical nerve repair products, including processed human nerve allografts. The company’s regulatory filings and research publications document a reliance on animal testing as a core component of its product development and FDA approval process. Its annual reports explicitly cite the completion of pre-clinical animal studies under FDA Good Laboratory Practice regulations as a standard requirement for its biologics license applications.
A 2023 peer-reviewed study, "In Vivo Efficacy of a Novel, Sutureless Coaptation Device for Repairing...", published in a scientific journal, details multiple small animal studies conducted to demonstrate the efficacy of an Axogen device. The research, which used animal models to test surgical nerve repair, was supported by Axogen and lists the company as providing the product and funding. This indicates the company directly commissions and relies on animal data for product validation.
Research Sources
1 organization
Related Exclusions
Wondering what we do invest in?
The Naughty List
A digest of changes to our exclusion list — new additions, removals, and the evidence behind them. We review the list continuously as new evidence surfaces.
Companies appear on our exclusion list based on our investment judgment — not because they've done anything illegal. This is a difference of values and opinion, not an accusation of wrongdoing. Exclusion does not constitute a recommendation against investing in any company, and absence from the list does not constitute a recommendation to invest.
This information is provided for educational and transparency purposes only and should not be relied upon as investment advice. Data is drawn from independent watchdogs, NGOs, government registries, and Ethical Capital's ongoing research — see Research Sources for the full list.
Ethical Capital LLC is a state-registered investment adviser in Utah (CRD #316032). Registration does not imply a certain level of skill or training.